CDC Health Advisory: Limited Availability of Nirsevimab in the United States
There is a current shortage of new respiratory syncytial virus (RSV) immunization nirsevimab (Beyfortus™) due to higher than anticipated demand.
In the context of limited supply during the 2023–2024 RSV season, CDC recommends prioritizing available nirsevimab 100mg doses for infants at the highest risk for severe RSV disease: young infants (age <6 months) and infants with underlying conditions that place them at highest risk for severe RSV disease.
Recommendations for using 50mg doses remain unchanged at this time. Avoid using two 50mg doses for infants weighing ≥5 kilograms (≥11 pounds) to preserve supply of 50mg doses for infants weighing <5 kilograms (<11 pounds). Providers should be aware that some insurers may not cover the cost of two 50mg doses for an individual infant.
Prenatal care providers should encourage pregnant people to receive RSVpreF vaccine (Abrysvo, Pfizer) during 32 weeks’ gestation through 36 weeks and 6 days’ gestation to prevent RSV lower respiratory tract infection in infants. To prevent severe RSV disease in infants, either the prenatal RSV vaccination or nirsevimab immunization for infants is recommended. Most infants will not need both. Please refer to the CDC Health Advisory for details, and find RSV Immunization Resources here.
Nirsevimab (Beyfortus™) Vaccine Supply Update
CDPH has received a limited number of Beyfortus™ 50mg (0.5 ml) dose formulation, expected to support ordering for the next 2-3 weeks. 0 doses for the 100mg (1.0mL) formulation have been allocated, as supply is not available.
CDPH is currently determining the provider types that doses would be made available to, potentially focusing on birthing hospitals, Tribal/Indian Health, and LHDs.
Sunsetting of U.S. Government (USG) COVID-19 Therapeutics Distribution Program
The U.S. Department of Health and Human Services (HHS) released its COVID-19 Therapeutics Commercialization Transition Guide on October 20, 2023, as it prepares to wind down government distribution of COVID-19 Therapeutics. Please use this HHS link for the winter COVID-19 treatments transition projected timeline and for further details. CDC Grant Agreement Funding Announcement
The California Department of Public Health (CDPH) has been awarded a supplemental grant to assess and improve adult immunization rates in Community Health Centers (CHCs). CDPH is seeking a large Federally Qualified Health Center (FQHC) to strengthen immunization practices in an identified adult patient population. For more details refer to the Grant Agreement Funding Announcement/Release. The My Turn and myCAvax Teams Appreciate Your Feedback! Please use the Vaccine Management Feedback Form to provide feedback and suggestions for the My Turn and myCAvax platforms. Support Opportunities
CDPH Immunization Branch Updates for Providers Webinar Please attend our weekly webinars to hear updates from CDPH subject matter experts and have your questions answered. Fridays 9:00AM – 10:30 AM Archived Sessions | Provider FAQs Provider Call Center For Program information: email providercallcenter@cdph.ca.gov or call (833) 502-1245 (Monday – Friday, 8AM–5PM) myCAvax Help Desk For technical issues (password resets, etc.): email myCAvax.HD@cdph.ca.gov or call (833) 502-1245, (Monday – Friday, 8AM – 5PM PT) System related training materials are available via the Knowledge Center in myCAvax and at EZIZ.org. My Turn Help Desk |
